Skip to main content
2024 Annual Meeting Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Translational Clinical Pharmacology
Symposia

Symposium 1: Clinical Pharmacology of Cannabinoids: Drug Development & Public Health Implications

Sunday, September 8, 2024
10:00 AM – 11:30 AM ET
Location:Grand Ballroom D
CE: 1.5

Target Audience:


The target audience for this Symposium is MDs, PharmDs and PhDs interested in the drug interaction potential of cannabinoids from a clinical and drug development perspective.



Description:


Cannabis use in the United States is steadily increasing despite federal restrictions. As of 2023, 19 states, Washington, DC, and Guam have legalized cannabis. Cannabis is estimated to have a 3.8% prevalence worldwide in adults making it the third most used drug after alcohol and tobacco. Further, although the majority of cannabis use is recreational, there is increasing interest in cannabinoids as therapeutics for a variety of diseases. However, the clinical pharmacology of cannabinoids is relatively understudied. Given the widespread prevalence of cannabis use, understanding drug interaction potential is critical both from a clinical and drug development perspective. Indeed, it has been recently argued that regular cannabis users should be considered a unique “special population” with respect to clinical pharmacology evaluation. Clinical pharmacology – including model-based approaches - is well-positioned to address emerging public health issues for cannabinoids including exposure-response relationships for impaired driving, environmental hazards of cannabis smoke, and pharmacokinetics in children, older adults, and lactating individuals.

Goals & Objectives:

Following the completion of this activity, the learner will be able to:
  • Identify important sources of variability in the pharmacokinetics of cannabinoids;
  • Describe clinically-relevant cytochrome P450-mediated cannabinoid-drug interactions;
  • Explain how baseline characteristics of a given clinical trial population could be different in regular cannabis users.

Presentations:

  • Population Pharmacokinetics & Exposure Response Relationships of Delta-9-Tetrahydrocannabinol

    Co-Chair & Faculty: Jeremiah D. Momper, PharmD, PhD – Univ of California San Diego

  • Cytochrome P450-Mediated Cannabinoid Drug Interactions in Adults

    Faculty: Mary F. Paine, PhD (she/her/hers) – Washington State Univ

  • Cannabinoid Pharmacokinetics in Special Populations: Pregnancy, Pediatrics & Hepatic Impairment

    Co-Chair & Faculty: Jashvant Unadkat, PhD – Univ of Washington

  • Chronic Cannabis Users: A New Special Population to Consider for Drug Development

    Faculty: Oliver Grundmann, PhD – Univ of Florida

  • Discussion, Questions & Answers, Learner Feedback & Evaluations